Posters

Intralesional ziv-aflibercept in a recurrent inflamed pterygium

Poster Details

First Author: W.Kheir LEBANON

Co Author(s):    A. Mansour              

Abstract Details

Purpose:

Few reports have addressed the therapy of inflamed or recurrent pterygia with anti-VEGF but none used the more recent aflibercept. Most have used bevacizumab because of its availability and economy followed by the more expensive ranibizumab. Aflibercept is available in a cheaper version, ziv-aflibercept, used for oncology with a cost is similar to that of bevacizumab. The current study analyzes the efficacy of ziv-aflibercept (Zaltrap) in controlling an inflamed recurrent pterygium at one week, 2 weeks, three weeks and one month after intralesional ziv-aflibercept injection.

Setting:

Rafic Hariri University Hospital, Beirut

Methods:

A young male worker had uneventful excision of a large pterygium. A few weeks later, recurrence was noted with a noticeable inflamed bed of the pterygium. After informed consent, 0.1 ml of ziv-aflibercept (2.5mg) was injected in the body of the pterygium and another 0.1 ml (2.5mg) in the advancing edge. The study received Institutional Review Board approval and received the registration NCT02486484.

Results:

One week later the recurring pterygium was avascular and regression was documented weekly over one month of followup without the use of topical medication.

Conclusions:

We used aflibercept for the first time in inflamed recurrent pterygium and documented remarkable constriction of dilated conjunctival vessels and halting of pterygium activity for one month of followup by weekly photographic monitoring. FINANCIAL DISCLOUSRE: NONE